FDA Eases Path for AI Radiology Tools
Published Date: 6/17/2026
Rule
Summary
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Radiology ML Software Now Class II
The FDA has classified radiological machine learning-based quantitative imaging software with a predetermined change control plan as Class II (special controls). The order is effective June 17, 2026, and the classification has been applicable since February 24, 2023.
Creates Predicate for Future Devices
Because FDA classified this device type via the De Novo process, the device can serve as a predicate for future devices of that type. That lets other device sponsors use the less burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application.
Premarket 510(k) Notification Required
The rule states that this device type is subject to premarket notification requirements under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA later exempts it under section 510(m).
New Technical and Labeling Requirements
The final order establishes special controls including: detailed design verification and validation (algorithm descriptions, training data details, independent test datasets, objective performance measures), documentation of planned modifications under the predetermined change control plan (PCCP), risk identification and mitigation for planned modifications, and labeling requirements (patient population, intended user, inputs/outputs, compatible hardware/protocols, performance summary with confidence intervals, failure situations, and PCCP details including version history).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19419, Sanjay Kumar: Final Debarment Order
Sanjay Kumar is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake goods. He didn’t respond to the FDA’s notice, so the ban starts on September 23, 2026. He can apply to end the ban anytime, but must follow special rules to keep info private.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
Previous / Next Documents
Previous: 2026-12165, Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
Next: 2026-12168, Security Zone; FIFA World Cup and Fan Fest 2026, Bayfront Park, Miami, FL
From June 13 to July 5, 2026, the Coast Guard is setting up a temporary security zone in Biscayne Bay near Bayfront Park, Miami, to keep everyone safe during the FIFA World Cup and Fan Fest. Boats can’t anchor or hang out in this zone unless they get special permission. This helps protect VIPs, players, and fans while making sure the waterfront stays secure during the big event.